This Page Is Inserted by IFW Operations and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problems Mailbox.



Title: API. IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND 11. ... CIL 21. C. T. METHODS OF TREATMENT FOR API. ANTIBODY MEDIATED PATHOMETERS.

ard J. VICTORIA, et al. No.: 10/044,844

Applicat No.: 10/044,844 Docket No.: 252312006103

Sheet 1_of 32

1/32

ACA Activity Effect of Serum vs Fish Gelatin




FIG. 1



Title: APL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND LEMETHODS OF TREATMENT FOR APL ANTIBODY-MEDIATED PATIFICATION OF TREATMENT FOR APPLICATION OF TREATMENT FO

Inventor ward J. VICTORIA, et al. Application No.: 10/044,844 Docket No.: 252312006103

Sheet 2 of 32

2/32

Immunoreactivity of ACA 6501-5A12 Peptide




FIG. 2



Title: APL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND UP TO THE THORSE OF TREATMENT FOR APL ANTIBODY-MEDIATED PATROGIES Invitation No.: 10/044,844 Docket No.: 252312006103

Sheet 3 of 32

3/32

Immunoreactivity of ACA-6626 with Solid Phase Peptides




FIG. 3



tor: Edward J. VICTORIA, et al. Application No.: 10/044,844 Docket No.: 252312006103

Sheet 4 of 32

4/32

Serum Crossreactivity of ACA 6501-5A12 Peptide




FIG. 4



Sheet 5 of 32

5/32

Serum Crossreactivity of ACA 6626-4D3 Peptide




FIG. 5

ACA ELISA of Serum 6501

O.D. 550 nm vs. Std. GPL UNITS

0.9

1.0

0.8


9.0

0.7

0.5

O.D. 550nm, 25 MIN.

0.4






FIG. 6A

6501: 1600dil./50 dil. x 70 GPL= 2240 GPL

90 100

8

2

50 60

4

30

20

9

0.0


0.2

0.1

0.3

Std. GPL units


FIG. 6B



ACA ELISA of Purified Ab fr. Serum 6501

FIG. 7

or 140.2GPL in 1 ug / ml





Sheet 8 of 32




FIG. 8






Title: APL IMMUNOREACTIVE PEPTIDES, CONDIGATES THE REGERAND OF THE PROPERTY OF


f: Edward J. VICTORIA, et al. Approaction No.: 10/044,844 Docket No.: 252312006103

Sheet 10 of 32



Sheet 11 of 32

Inhibition of (3B10)4/6501 Derived by 6501 Derived Peptide Monomer with 400 Diluted Ser.6501



11/32





Title: APL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND LOS METHODS OF TREATMENT FOR APL ANTIBODY-MEDI

Inventor dward J. VICTORIA, et al. Application No.: 10/044,844 Docket No.: 252312006103

Sheet 12 of 32

12/32

Inhibition of CdI-2.3% Hu Ser.(no IgG) by Modified Peptides 3G3 with 400x Diluted Serum 6501





FIG. 12






Investigation No.: 10/044,844
Docket No.: 252312006103

Sheet 13 of 32

13/32

Inhibition of (3B10)4/6501 Derived by Truncated or Non-Truncated 3B10 with 400 Diluted Serum 6501



- ____ 139:----PCLLLAPDRCPG = 6.9 ug inhibited 50% ser.6501
- 142:--GPCLLLAPDRCPG = 0.7 ug inhibited 50% ser.6501
- ---- 143:AGPCLLLAPDRCPG = 0.9 ug inhibited 50% ser.6501
 - blank
- —— 50% inhibition



Edward J. VICTORIA, et al. Approaction No.: 10/044,844 Docket No.: 252312006103

Sheet 14 of 32

14/32




FIG. 14


Cross reactivity of peptide LJP 688 with aff-ACA

Cardiolipin/ß2-GPI-coated plates

Invention I ward J. VICTORIA, et al. Application No.: 10/044,844 Docket No.: 252312006103


Sheet 15 of 32

15/32



1.0 mg/mL peptide

LJP 685-MTU-DABA-PEG (COMPOUND 36)



MEAN AND S.D. 5 MICE/GROUP

FIG. 16


LJP 685-ATU-MTU-AHAB-TEG (COMPOUND 35)

ard J. VICTORIA, et al.

** Application No.: 10/044,844 Docket No.: 252312006103

Sheet 17 of 32





ANTI-685. ABC AT 10-8M



Title: APL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOFIND LA CONTROL OF TREATMENT FOR APL ANTIBODY-MEDIATED GIES

Invent ward J. VICTORIA, et al. Application No.: 10/044,844 Docket No.: 252312006103

Sheet 18 of 32 /




FIG. 18



Title: APL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND THE PROPERTY OF THE PEPTIDES OF TREATMENT FOR APL ANTIBODY MEDIATED LOGIES

Ir : Edward J. VICTORIA, et al. Application No.: 10/044,844 Docket No.: 252312006103

Sheet 19 of 32





FIG. 19



Sheet 20 of 32








FIG. 20B




Invention Invention Invention Invention No.: 10/044,844
Docket No.: 252312006103

Sheet 21 of 32

21/32

Inhibition of $\mbox{\ensuremath{\mathbb{G}_2}GP-1}$ by 6501-Derived Peptides with 350x Diluted Serum 6501





Title: APL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOPANDUL. SUFFELL STATES OF TREATMENT FOR APL ANTIBODY MEDIATED PARTIES.

Inventor dward J. VICTORIA, et al. Application No.: 10/044,844 Docket No.: 252312006103

Sheet 22 of 32

22/32

6701 Titration of CB2*-F: (FITC)-GPCILLARDRCG-CO₂-




FIG. 22




Inven ward J. VICTORIA, et al. Application No.: 10/044,844 Docket No.: 252312006103

Sheet 23 of 32

23/32

6501 Titration of CB2*-F: (FITC)-GPCILLARDRCG-CO₂-





Title: APL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOFIAND IT METHODS OF TREATMENT FOR APL ANTIBODY MEDIATED PAGES

Jward J. VICTORIA, et al.

Application No.: 10/044,844 Docket No.: 252312006103

Sheet 24 of 32

24/32

6501 Titration of CB2*-F: (FITC)-GPCILLARDRCG-CO₂-





FIG. 24





Inventor liward J. VICTORIA, et al. Application No.: 10/044,844 Docket No.: 252312006103

Sheet 25 of 32

25/32

Displacement of CB2*-F from 6701 using 1.04 eq. of CB2*: GPCILLARDRCG-CO₂





FIG. 25





Edward J. VICTORIA, et al. Application No.: 10/044,844 Docket No.: 252312006103

Sheet 26 of 32 ,

26/32

CB2* Titration of CB2*-F/6701: CB2*: GPCILLARDRCG-CO₂-






FIG. 26



Title: APL IMMUNOREACTIVE PEPTIDES, CONJUGATES FHEREOE AND LL . O 42 40 3 METHODS OF TREATMENT FOR APL ANTIBODY-MEDIATED.

Invento ard J. VICTORIA, et al. Application No.: 10/044,844
Docket No.: 252312006103

Sheet 27 of 32

27/32

3B10 Titration of CB2*-F/6701: 3B10: AGPCLLLAPDRCPG-CO₂-





FIG. 27



Title: APL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOFIAND METHODS OF TREATMENT FOR APL ANTIBODY-MEDIATED

Investigation No.: 10/044,844 Docket No.: 252312006103

Sheet 28 of 32





Title: APL IMMUNOREACTIVE PEPTIDES, CONJUGATES PHEREOF AND LIFE OF AND LIFE OF

Invento card J. VICTORIA, et al. Application No.: 10/044,844 Docket No.: 252312006103

Sheet 30 of 32




FIG. 30



Title: APL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND 11 METHODS OF TREATMENT FOR APL ANTIBODY-MEDIATED

Invents vard J. VICTORIA, et al. Application No.: 10/044,844 Docket No.: 252312006103

Sheet 31 of 32




FIG. 31



Title: APL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOFIANDLE LANGE OF TREATMENT FOR APL ANTIBODY-MEDIATED PATITUDES.

Inventor, and J. VICTORIA, et al. Application No.: 10/044,844 Docket No.: 252312006103

Sheet 32 of 32

32/32

Tolerogen	Dose	Delivery	
(LJP685) 4/MTU-AHAB-TEG	50 nMoles	1μl/hr 3 Days	
Saline	(100 µl)	1µl/hr 3 Days	
(LJP685) 4/MTU-AHAB-TEG	50 nMoles	0.5µl/hr 7 Days] *
(LJP685) 4/MTU-AHAB-TEG	50 nMoles	Bolus	
Saline	(500 µl)	Bolus	
			0 200 400 600 800 1000 ANTI-685, ABC AT 10 -8M

FIG. 32



Creation date: 06-03-2004

Indexing Officer: NKING - NICOLE KING

Team: OIPEBackFileIndexing

Dossier: 10044844

Legal Date: 11-14-2003

Total number of pages: 7

No.	Doccode	Number of pages
1	CTRS	7

Remarks:		

Order of re-scan issued on